ALK and non-small cell lung carcinoma: Anaplastic lymphoma kinase (ALK) is a similar target; NSCLC patients with ALK rearrangement have a poor prognosis, but also have a better response to ALK-TKIs, resulting in a better prognosis after treatment with them [29].